{"id":14935,"date":"2020-10-06T10:36:46","date_gmt":"2020-10-06T08:36:46","guid":{"rendered":"https:\/\/idibell.cat\/?p=14935"},"modified":"2020-10-06T10:36:46","modified_gmt":"2020-10-06T08:36:46","slug":"un-estudi-de-biomarcadors-en-sequenciacio-de-ladn-demostra-que-la-quantitat-i-clonalitat-de-tcrs-sassocia-clarament-al-pronostic-del-cancer-colorectal","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2020\/10\/un-estudi-de-biomarcadors-en-sequenciacio-de-ladn-demostra-que-la-quantitat-i-clonalitat-de-tcrs-sassocia-clarament-al-pronostic-del-cancer-colorectal\/","title":{"rendered":"Un estudi de biomarcadors en seq\u00fcenciaci\u00f3 de l\u2019ADN demostra que la quantitat i clonalitat de TCRs s\u2019associa clarament al pron\u00f2stic del c\u00e0ncer colorectal"},"content":{"rendered":"<p>El <strong>c\u00e0ncer colorectal<\/strong> (CCR) \u00e9s el tercer m\u00e9s freq\u00fcent arreu del m\u00f3n amb m\u00e9s d\u2019un mili\u00f3 i mig de casos nous diagnosticats anualment. Aproximadament el 20% del pacients diagnosticats, en estadi II, experimenten recaigudes despr\u00e9s de que els hi hagin realitzat la cirurgia. Encara no existeix cap marcador que identifiqui pacients en estadi II amb risc de la recaiguda. Per tant, \u00e9s important poder identificar biomarcadors pron\u00f2stics per aquest entorn espec\u00edfic.<\/p>\n<p>Fins a dia d\u2019avui, ja se sabia que <strong>la infiltraci\u00f3 de les c\u00e8l\u00b7lules T<\/strong> (un tipus de limf\u00f2cit que forma part del sistema immunitari adaptatiu) t\u00e9 un paper important en la superviv\u00e8ncia dels pacients amb c\u00e0ncer colorectal. Aix\u00ed doncs, utilitzant una nova t\u00e8cnica\u00a0 anomenada \u2018<strong>immuno seq\u00fcenciaci\u00f3 dels TCR<\/strong>\u2019, en mostres de m\u00e9s de 600 pacients amb c\u00e0ncer colorectal, s\u2019ha volgut comprovar la utilitat d\u2019aquest nou biomarcador. Aquesta nova t\u00e8cnica mesura tant la quantitat de limf\u00f2cits T infiltrants com la seva clonalitat, que \u00e9s la diversitat de limf\u00f2cits que reconeixen dianes diferents.<\/p>\n<p>Aquest estudi ha estat una col\u00b7laboraci\u00f3 liderada per en V\u00edctor Moreno responsable del <strong>Programa d\u2019An\u00e0lisi de Dades Oncol\u00f2giques<\/strong> (PADO) de l\u2019Institut Catal\u00e0 d\u2019Oncologia (<a href=\"http:\/\/ico.gencat.cat\/ca\/inici\">ICO<\/a>), l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (<a href=\"https:\/\/idibell.cat\/recerca\/area-de-cancer\/programa-de-mecanismes-molleculars-i-terapia-experimental-en-oncologia-oncobell\/cancer-colorectal\/\">IDIBELL<\/a>), el CIBERESP i Universitat de Barcelona, i el seu equip. En el projecte han participat el grup de recerca liderat pel Dr.Steven Gruber, del \u2018City of Hope National Medical Center\u2019 de Los Angeles, EUA, el Dr. Harlan Robins, CEO de l\u2019empresa Adaptive Biotechnologies, spin off del Fred Hutch Cancer Research Center de Seattle, \u00a0EUA, i el Prof. Gad Rennert, del Carmel Medical Center and Technion, Haifa, Israel.<\/p>\n<p>&nbsp;<\/p>\n<h3>Com s\u2019ha realitzat aquest estudi?<\/h3>\n<p>&nbsp;<\/p>\n<p>Utilitzant aquesta nova t\u00e8cnica d\u2018immuno seq\u00fcenciaci\u00f3 del TCR s\u2019han seq\u00fcenciat un total de <strong>640 tumors de c\u00e0ncer colorectal<\/strong> de quatre estudis diferents, tres de pacients de l\u2019ICO l\u2019Hospitalet i un d\u2019Israel. Aix\u00ed doncs, a trav\u00e9s d\u2019aquesta nova t\u00e8cnica, a diferencia dels altres m\u00e8todes, mitjan\u00e7ant la seq\u00fcenciaci\u00f3 de les regions TCR (receptor de limf\u00f2cits que reconeixen ant\u00edgens tumorals) s\u2019ha obtingut tant l\u2019abund\u00e0ncia de la c\u00e8l\u00b7lula T i que infiltra el tumor com l\u2019\u00edndex de clonalitat de les mateixes.<\/p>\n<p>Els resultats obtinguts han demostrat que la combinaci\u00f3 d\u2019ambdues variables, quantitat i clonalitat, s\u2019associen clarament al pron\u00f2stic. Les mostres\u00a0 amb m\u00e9s quantitat de TCR i m\u00e9s diversitat de clons s\u00f3n les que presenten un millor pron\u00f2stic de la malaltia. Segons el cap del Programa d\u2019An\u00e0lisi de Dades Oncol\u00f2giques (PADO) de l\u2019ICO-IDIBELL, V\u00edctor Moreno, <em>\u201cels resultats d\u2019aquest estudi demostren que a nivells m\u00e9s alts de TCR, i una major diversitat de repertori TCR, s\u2019associa a un millor pron\u00f2stic en aquest grup espec\u00edfic de pacients on encara no existeixen marcadors clars de recurr\u00e8ncia\u201d. <\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u2022\tPer a realitzar aquest estudi s\u2019ha utilitzat una nova t\u00e8cnica anomenada \u2018immuno seq\u00fcenciaci\u00f3 del receptor de les c\u00e8l\u00b7lules T (TCR)\u2019 que permet obtenir tant el nombre de limf\u00f2cits T que infiltren el tumor com l\u2019\u00edndex de clonalitat del mateixos.<\/p>\n","protected":false},"author":8,"featured_media":14939,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,375,447],"tags":[],"class_list":["post-14935","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-colorectal","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell"],"publishpress_future_action":{"enabled":false,"date":"2025-01-25 04:43:07","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/14935","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=14935"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/14935\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/14939"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=14935"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=14935"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=14935"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}